BiomeBank
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BiomeBank - overview
Established
2018
Location
Adelaide, SA, Australia
Primary Industry
Biotechnology
About
Based in Australia, and founded by Sam Costello (CEO), and Rob Bryant in 2018, COST-BRY Pty Ltd. doing business as BiomeBank is a clinical-stage biotechnology company developing microbial therapies to prevent disease by restoring gut microbial ecology. In December 2022, BiomeBank raised AUD 10. 65 million in Series A funding from investors Artesian and Ellerston Capital.
The firm offers a microbiome-based therapy that can be administered to patients during enema or colonoscopy to help treat patients suffering from chronic diseases such as ulcerative colitis, Crohn’s disease, and irritable bowel syndrome. The product is encapsulated and freeze-dried for oral delivery and also offered as a syringe frozen for colonoscopy and enema delivery. The company intends to use the December 2022 funding for the discovery and development of second-generation cultured therapies.
Current Investors
Ellerston Capital, Artesian, The Hospital Research Foundation Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.biomebank.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
BiomeBank - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.